Atrial fibrillation following subconjunctival injection of mydricaine number 02
Related Experiment Video
Updated: Jul 19, 2026

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
Published on: December 7, 2016
Abstract:
Mydricaine is a mydriatic agent used as a subconjunctival injection to maintain perioperative mydriasis. The drug consists of a mixture of 1.3 mg atropine sulphate, 0.12 mg adrenaline and 8.4 mg procaine hydrochloride in a single vial of 0.4 mL. It is common practice to use mydricaine injections during vitreoretinal surgery in the Royal Adelaide Hospital. Even though the drug is used widely in many vitreoretinal centres, mydricaine is not listed in the British National Formulary nor Monthly Index of Medical Specialities. Therefore, case reports provide the main forum for reporting side-effects.
